Carl Icahn
Carl Icahn is a billionaire financier, ranking #18 on the 2007 Forbes 400 list with an estimated net worth of $14.5 billion.
Icahn built a name for himself in the 1980s as a corporate raider. After keeping quite for years, Icahn made a major comeback as a 'activist investor'. An activist investor agitates companies for changes, including buyouts, share buybacks, and dividend increases.
Icahn has successfully pushed for changes at Time Warner (NYSE: TWX) and Temple-Inland (NYSE: TIN), among others. Icahn won board seats at Motorola (NYSE: MOT) after first failing.
In 2007, Icahn's activism successfully pushed biotech company MedImmune into a sales agreement with AstraZeneca (NYSE: AZN). Icahn is also involved with biotech company Imclone Systems (Nasdaq: IMCL), where he is Chairman of the Board.
In early, 2008 Icahn activist target BEA Systems (Nasdaq: BEAS) was sold to Oracle (Nasdaq: ORCL). Icahn held a 13% stake in BEA.
Icahn is also involved with developments at Biogen Idec (Nasdaq: BIIB) and WCI Communities (NYSE: WCI), which both unsuccessfully explored sales. WCI rejected a $22 per share takeover offer from Icahn in early 2007, only to see its stock plummet on the housing slowdown.
In 2008, Icahn targeted Yahoo! (Nasdaq: YHOO) after the Internet company failed to work out an acceptable merger agreement with Microsoft (Nasdaq: MSFT) Microsoft walked away from its bid for Yahoo! after months of bickering.
View Older Stories
-
Carl Icahn Raises Stakes In Take-Two (TTWO) and Genzyme (GENZ), Slashes Stake in Yahoo! (YHOO)
-
Icahn's 13Fs Show No Major Changes (YHOO, MOT, BIIB, AMLN, LGF)
-
Icahn Says Future Is Big Pharma Will Buy Biotech (BIIB, AMLN)
-
Amylin (AMLN) Reports Preliminary Tabulation of Annual Meeting Results
-
Amylin (AMLN) Said No More Than Two Dissident Directors Elected
-
Amylin (AMLN) Has Lost At Least 2 Board Seats in Battle with Icahn -CNBC
-
Amylin (AMLN) Issues Response to Eastbourne Letter
-
Icahn Urges Amylin (AMLN) Shareholders to Vote for Eastbourne Slate; 3 Independent Proxy Advisors Support Icahn's Nominees
-
Icahn Boosts Stake in American Railcar (ARII), Maintains Large Yahoo! (YHOO) and Motorola (MOT) Holdings
-
Icahn Capital: Sells - APC, TIN, WMB; Buys - LGF, TTWO, AMLN
-
Icahn Fires Back Following Amylin's (AMLN) Letter
-
Founding CEO of Amylin (AMLN), Greene, to Vote for Eastbourne Slate
-
Amylin (AMLN) Sends Letter to Shareholders
-
Amylin (AMLN) Agrees With Carl Icahn Affiliates, Eastbourne on Talks -Bloomberg
-
Carl Icahn is asking Amylin (AMLN) to allow discussions with Eastbourne
-
Icahn Sends Letter to Amylin's (AMLN) Cook, Wilson: Wouldn't Sell Co. for Less Than $30/Share
-
Icahn Wouldn't Recommend Selling Amylin (AMLN) for Less Than $30/Sh - Dow Jones
-
Icahn Said Amylin (AMLN) Misstated and Mischaracterized Conversations, Plans Letter
-
Icahn to Respond to Letter from Amylin (AMLN) -DJ
-
After-Hours Movers 4/16: TEL, DRYS, TPX, ICUI Higher; CYT, MGM, WRI, AMLN, BIIB Lower
-
Icahn Sends Letter to Amylin (AMLN): Demands Chairman's Resignation
-
Eastbourne Capital Sends Letter to Amylin (AMLN); Seeking 5 Seats on Board
-
Icahn Raises Stakes In AMLN, LGF, WMB, YHOO; Cuts Stakes in TIN, LEA
-
Icahn Raises Stake Amylin Pharma (AMLN) To 9.4%
-
Amylin (AMLN) Has Investors Fired-Up for Change
-
Like ImClone, Icahn Will Get Amylin (AMLN) Sold
-
Unusual 11 Mid-Day Movers 11/17: GTE, CTS, PHH, ARTG Higher; UTHR, DFT, BIDU, HIG Lower
-
Eastbourne Capital May Talk With Amylin Pharma (AMLN) About A Possible Sale
-
Amylin Pharma (AMLN) Higher After Icahn Boosts Stake
-
Icahn Down $60M on Healthcare Stocks This Week (AMLN, BIIB, CYBX, REGN, FOLD)
-
Amylin Pharm (AMLN) Sinks On Byetta Pancreatitis Cases; Smart Money May Be Moving In
-
Icahn's Icahn Capital Bumps Stake in Motorola (MOT), Shows New Small Stake in Emisphere (EMIS)
-
Icahn Has A Happy Day, Racks Up Gains of At Least $350M
-
Biotech Takeover Buzz Hot and Heavy After ImClone Offer (ONXX, OSIP, BIIB, AMLN, XPNT, CYPB, ISPH)
-
Pre-Open Movers 7/31: Imclone (IMCL) Surges On Takeover Offer; Akamai (AKAM) Sinks On Results/Guidance
-
Amylin Pharmaceuticals (AMLN) Could Be One To Watch On ImClone Bid
-
Carl Icahn Boosts Stake in Amylin Pharma (AMLN) to 6.5%, Seeks Additional Talks
-
Carl Icahn files 13D on Amylin (AMLN), boosts stake to 6.5%. Seeks talks
-
Pre-Open Movers 5/16: Pharmacopeia (PCOP) Up on Positive Drug Data, Dynavax (DVAX) Lower on Drug Data
-
After-Hours Movers 5/15: Noah Education (NED) Up on Results/Guidance; KongZhong (KONG) Lower on Results
-
Icahn's Icahn Capital Shows New 6.3M Share Stake in Amylin Pharma (AMLN)
